cabozantinib
exelixis
['atlantis', 'cabozantinib', 'urothelial', 'urothelial carcinoma']
asco 2022 video: robert jones explains why the atlantis trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of vegfr-targeted therapies in this tumor type.
Springer Healthcare IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.